Pravastatin Sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H318560

CAS#: 81131-70-6 (sodium)

Description: Pravastatin Sodium is an antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase Pravastatin competitively inhibits hepatic hydroxymethyl-glutaryl coenzyme A reductase, the enzyme which catalyzes the conversion of HMG-CoA to mevalonate, a key step in cholesterol synthesis. This agent lowers plasma cholesterol and lipoprotein levels, and modulates immune responses by suppressing MHC II on interferon gamma-stimulated, antigen-presenting cells such as human vascular endothelial cells.

Chemical Structure

img
Pravastatin Sodium
CAS# 81131-70-6 (sodium)
Instruction

Theoretical Analysis

Hodoodo Cat#: H318560
Name: Pravastatin Sodium
CAS#: 81131-70-6 (sodium)
Chemical Formula: C23H35NaO7
Exact Mass: 0.00
Molecular Weight: 446.516
Elemental Analysis: C, 61.87; H, 7.90; Na, 5.15; O, 25.08

Price and Availability

Size Price Availability Quantity
5g USD -1 2 Weeks
10mg USD 120 2 Weeks
25mg USD 190 2 Weeks
50mg USD 350 2 Weeks
100mg USD 550 2 Weeks
200mg USD 950 2 Weeks
500mg USD 1650 2 Weeks
1g USD 2650 2 Weeks
2g USD 3850 2 Weeks
Bulk inquiry

Related CAS #: 81131-70-6 (sodium)   85956-22-5 (lactone)   81093-37-0 (free acid)    

Synonym: Pravastatin Sodium; Mevalotin; Elisor; Lipostat; Pravachol; Pravaselect; Apo-Pravastatin; Apotex Brand of Pravastatin Sodium; Aventis Brand of Pravastatin Sodium; Bristacol; Bristol-Myers Squibb Brand of Pravastatin Sodium; CS 514; CS-514; CS514; Elisor;

IUPAC/Chemical Name: sodium;(3R,5R)-7-[(1S,2S,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoate

InChi Key: VWBQYTRBTXKKOG-IYNICTALSA-M

InChi Code: InChI=1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

SMILES Code: CCC(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC(CC(CC(=O)[O-])O)O)O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 446.52 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Suzuki M, Kanamori M, Hashimoto T, Hashimoto Y, Funakoshi R, Sasaki T. A
laboratory data-based evaluation of the efficacy and safety of generic
pravastatin sodium for long-term use. J Pharm Health Care Sci. 2015 Dec 18;2:1.
doi: 10.1186/s40780-015-0033-4. eCollection 2016. PubMed PMID: 26819746; PubMed
Central PMCID: PMC4729182.


2: Feng J, Liu Z, Yan Y, Hu M, Lu L, You W. [Preparation and performance of
pravastatin sodium-loaded chitosan microspheres]. Nan Fang Yi Ke Da Xue Xue Bao.
2015 Jun;35(6):879-82. Chinese. PubMed PMID: 26111689.


3: Tayel SA, El-Nabarawi MA, Tadros MI, Abd-Elsalam WH. Duodenum-triggered
delivery of pravastatin sodium via enteric surface-coated nanovesicular
spanlastic dispersions: development, characterization and pharmacokinetic
assessments. Int J Pharm. 2015 Apr 10;483(1-2):77-88. doi:
10.1016/j.ijpharm.2015.02.012. Epub 2015 Feb 7. PubMed PMID: 25666025.


4: Ma YR, Zhou Y, Zhang GQ, Rao Z, Huang J, Wei YH, Wu XA. [Simultaneous
determination of repaglinide and pravastatin sodium in rat plasma by LC-ms/MS and
its application on pharmacokinetic interactions study]. Yao Xue Xue Bao. 2014
Jan;49(1):72-7. Chinese. PubMed PMID: 24783509.


5: Al-Badr AA, Mostafa GA. Pravastatin sodium. Profiles Drug Subst Excip Relat
Methodol. 2014;39:433-513. doi: 10.1016/B978-0-12-800173-8.00008-8. Review.
PubMed PMID: 24794911.


6: Yedurkar P, Dhiman MK, Petkar K, Sawant K. Biopolymeric mucoadhesive bilayer
patch of pravastatin sodium for buccal delivery and treatment of patients with
atherosclerosis. Drug Dev Ind Pharm. 2013 May;39(5):670-80. doi:
10.3109/03639045.2012.687379. Epub 2012 May 26. PubMed PMID: 22630116.


7: Maurya SK, Bali V, Pathak K. Bilayered transmucosal drug delivery system of
pravastatin sodium: statistical optimization, in vitro, ex vivo, in vivo and
stability assessment. Drug Deliv. 2012 Jan;19(1):45-57. doi:
10.3109/10717544.2011.644348. Epub 2011 Dec 23. PubMed PMID: 22191789.


8: Garg Y, Pathak K. Design and in vitro performance evaluation of purified
microparticles of pravastatin sodium for intestinal delivery. AAPS PharmSciTech.
2011 Jun;12(2):673-82. doi: 10.1208/s12249-011-9626-x. Epub 2011 May 19. PubMed
PMID: 21594729; PubMed Central PMCID: PMC3134671.


9: Kumar Y, Philip B, Pathak K. High-efficiency loading and controlled release of
highly water-soluble drug, pravastatin sodium by use of cross-linked
β-cyclodextrin. Int J Pharm Investig. 2011 Jan;1(1):10-6. doi:
10.4103/2230-973X.76722. PubMed PMID: 23071914; PubMed Central PMCID: PMC3465117.


10: Shidhaye SS, Thakkar PV, Dand NM, Kadam VJ. Buccal drug delivery of
pravastatin sodium. AAPS PharmSciTech. 2010 Mar;11(1):416-24. doi:
10.1208/s12249-010-9381-4. Epub 2010 Mar 19. PubMed PMID: 20300898; PubMed
Central PMCID: PMC2850451.


11: Kalomenidis I, Papiris S, Loukides S. Bilateral pleural effusions associated
with pravastatin sodium treatment. Eur Respir J. 2007 Nov;30(5):1022. PubMed
PMID: 17978161.


12: Miyazaki A, Koieyama T, Shimada Y, Kikuchi T, Ito K, Kasanuki N, Koga T.
Pravastatin sodium, an inhibitor of HMG-CoA reductase, decreases HDL cholesterol
by transfer of cholesteryl ester from HDL to VLDL in Japanese white rabbits. J
Atheroscler Thromb. 2004;11(1):22-8. PubMed PMID: 15067195.


13: Miyazaki A, Koieyama T, Shimada Y, Kikuchi T, Nezu H, Ito K, Kasanuki N, Koga
T. Effects of pravastatin sodium on mevalonate metabolism in common marmosets. J
Biochem. 2002 Sep;132(3):395-400. PubMed PMID: 12204108.


14: Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW. Pravastatin sodium
activates endothelial nitric oxide synthase independent of its
cholesterol-lowering actions. J Am Coll Cardiol. 1999 Jan;33(1):234-41. PubMed
PMID: 9935036.


15: Muramatsu S, Komokata Y, Tanaka Y, Takahagi H. Metabolism of pravastatin
sodium by 3 alpha-hydroxysteroid dehydrogenase. Biol Pharm Bull. 1997
Nov;20(11):1199-203. PubMed PMID: 9401732.


16: Fujioka T, Tsujita Y, Shimotsu H. Induction of fatty acid synthesis by
pravastatin sodium in rat liver and primary hepatocytes. Eur J Pharmacol. 1997
Jun 11;328(2-3):235-9. PubMed PMID: 9218706.


17: Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of
pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology
in type II hyperlipoproteinemia. Atherosclerosis. 1996 May;122(2):225-33. PubMed
PMID: 8769685.


18: Shiomi M, Ito T, Tsukada T, Yata T, Watanabe Y, Tsujita Y, Fukami M,
Fukushige J, Hosokawa T, Tamura A. Reduction of serum cholesterol levels alters
lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on
atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol. 1995
Nov;15(11):1938-44. PubMed PMID: 7583574.


19: Fujioka T, Nara F, Tsujita Y, Fukushige J, Fukami M, Kuroda M. The mechanism
of lack of hypocholesterolemic effects of pravastatin sodium, a
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats. Biochim
Biophys Acta. 1995 Jan 3;1254(1):7-12. PubMed PMID: 7811749.


20: Dumousseaux C, Muramatsu S, Takasaki W, Takahagi H. Highly sensitive and
specific determination of pravastatin sodium in plasma by high-performance liquid
chromatography with laser-induced fluorescence detection after immobilized
antibody extraction. J Pharm Sci. 1994 Nov;83(11):1630-6. PubMed PMID: 7891286.